NR vs. NMN: dosing and effects on NAD+ levels | David Sinclair
Two NAD+ precursors, nicotinamide riboside and nicotinamide mononucleotide, have been shown to ameliorate age-associated diseases in animals. They are well-tolerated at high doses and effectively raise NAD+ levels. Evidence suggests that these molecules, often referred to as "NAD+ boosters," may increase levels of NAD+ in humans, too; however, the doses used in some of the studies equate to far less than what was provided in the rodent studies. Currently, only nicotinamide riboside has been shown to raise plasma NAD+ levels and may possibly have beneficial health effects in humans. Future research, focused on "super boosters," may have relevance for treating complex diseases such as diabetes, heart disease, cancer, and Alzheimer's. In this clip, Dr. David Sinclair discusses the current state of research on the NAD+ boosters nicotinamide riboside and nicotinamide mononucleotide.
Member support keeps us strong.
If you enjoy the fruits of , you can participate in helping us to keep improving it. Creating a pay-what-you-can subscription does just that! Plus, we throw in occasional member perks and, more importantly, churn out the best possible content without concerning ourselves with the wishes of any dark overlords.
Our website is 100% supported by people like you through this pay-what-you-can mechanism.
Fundamentals$15 / month
Loyal Fan$25 / month
Super Fan$50 / month
Power Supporter$125 / month
Heroic Supporter$250 / month